We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+31.56%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.85B
AUM Growth
+$887M
Cap. Flow
+$249M
Cap. Flow %
6.46%
Top 10 Hldgs %
72.18%
Holding
61
New
10
Increased
9
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$140M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.7M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$80.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$79.9M
5
TNGX icon
Tango Therapeutics
TNGX
+$40M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$131M
2
SWTX
SpringWorks Therapeutics
SWTX
+$80M
3
RLAY icon
Relay Therapeutics
RLAY
+$35M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$30.2M
5
SLRN
ACELYRIN
SLRN
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMAXW
51
DELISTED
CareMax, Inc. Warrant
CMAXW
$49.8K ﹤0.01%
100,000
– –
ALLO icon
52
Allogene Therapeutics
ALLO
$573M
– –
-4,488,200
Closed -$14.2M
APLS
53
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-732,500
Closed -$27.9M
PRLD icon
54
Prelude Therapeutics
PRLD
$370M
– –
-1,157,452
Closed -$3.58M
PRME icon
55
Prime Medicine
PRME
$558M
– –
-600,000
Closed -$5.72M
RLAY icon
56
Relay Therapeutics
RLAY
$3.99B
– –
-4,163,824
Closed -$35M
RVMD icon
57
CALL
Revolution Medicines
RVMD
$39.1B
– –
-31,300
Closed -$866K
SLRN
58
DELISTED
ACELYRIN
SLRN
– –
-1,402,201
Closed -$14.3M
SWTX
59
DELISTED
SpringWorks Therapeutics
SWTX
– –
-3,460,208
Closed -$80M
TPST icon
60
Tempest Therapeutics
TPST
$13.9M
– –
-71,615
Closed -$284K
DCPH
61
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-993,000
Closed -$12.6M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2023 Portfolio in Review

As of Q4 2023, EcoR1 Capital held 61 positions worth $3.85B, up 30% from $2.96B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital deployed $249M of net new capital in Q4 2023, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was argenx: 300,997 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $131M trimmed.

  • EcoR1 Capital's largest Q4 2023 buy was argenx: 300,997 shares worth $115M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $92.7M increase.
  • EcoR1 Capital's biggest Q4 2023 reduction was Revolution Medicines, cutting an estimated $131M.
  • EcoR1 Capital fully exited SpringWorks Therapeutics in Q4 2023, selling an estimated $80M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $3.85B portfolio in Q4 2023.
  • EcoR1 Capital opened 10 new positions and closed 10 in Q4 2023.
  • EcoR1 Capital's portfolio value rose 30% quarter-over-quarter to $3.85B.

Based on EcoR1 Capital's 13F filing for Q4 2023, filed 14 Feb 2024.